3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
19
Carcinoma, Hepatocellular
18
Pancreatic Neoplasms
14
Colorectal Neoplasms
12
Esophageal Neoplasms
9
Neoplasm Metastasis
8
Esophageal Squamous Cell Carcinoma
7
Biliary Tract Neoplasms
7
Lung Neoplasms
6
Liver Neoplasms
6
Cholangiocarcinoma
6
Breast Neoplasms
6
Neoplasms
5
Colonic Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Melanoma
3
Sarcoma
2
Rectal Neoplasms
2
Advanced Pancreatic Cancer
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Tuberous Sclerosis
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Resectable Esophageal Squamous Cell Carcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Cancer Metastatic
1
Ovarian Neoplasms
1
Oligometastatic Gastrointestinal Cancer
1
Interventions
Sorafenib
5
lenvatinib
3
sintilimab
2
pembrolizumab
2
halofantrine
2
camrelizumab
2
atezolizumab
2
Immunotherapy
2
Blood Specimen Collection
2
Bevacizumab
2
Antibodies
2
trifluridine tipiracil drug combination
1
trametinib
1
toripalimab
1
titanium silicide
1
tislelizumab
1
linifanib
1
genexol-PM
1
gadolinium ethoxybenzyl DTPA
1
fluorocholine
1
fisogatinib
1
ficlatuzumab
1
durvalumab
1
bavituximab
1
avelumab
1
User-Centered Design
1
Sunitinib
1
Sufentanil
1
Standard of Care
1
Shadowing Technique, Histology
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liver Diseases
×
Injections
×
Gastrointestinal
×
Clear all
NCT04727307
2025-09-30
AB-LATE02
University Hospital, Montpellier
Phase 2
Recruiting
202 enrolled